Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Titel:
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Auteur:
Danese, Silvio Panaccione, Remo Feagan, Brian G Afzali, Anita Rubin, David T Sands, Bruce E Reinisch, Walter Panés, Julián Sahoo, Aparna Terry, Natalie A Chan, Daphne Han, Chenglong Frustaci, Mary Ellen Yang, Zijiang Sandborn, William J Hisamatsu, Tadakazu Andrews, Jane M D'Haens, Geert R